Isachenko V, Maettner R, Petrunkina A M, Sterzik K, Mallmann P, Rahimi G, Sanchez R, Risopatron J, Damjanoski I, Isachenko E
Department of Obstetrics and Gynecology, Cologne University, Cologne, Germany.
J Androl. 2012 May-Jun;33(3):462-8. doi: 10.2164/jandrol.111.013789. Epub 2011 Jun 30.
The aim of this study was to develop and to test the standardized aseptic technology of permeable cryoprotectant-free vitrification of human spermatozoa in capillaries (for intracytoplasmic sperm injection [ICSI] or in vitro fertilization [IVF]). To test the effect of vitrification on basic sperm parameters, each of 68 swim-up-prepared ejaculates from oligo-astheno-terato-zoospermic patients were aliquoted and distributed into 3 groups: 1) nontreated control, 2) 10 μL of spermatozoa cryopreserved by slow conventional freezing with glycerol-contented medium, and 3) 10 μL of spermatozoa vitrified in 50-μL plastic capillaries in culture medium with 0.25 M sucrose. Spermatozoa motility (1, 24, and 48 hours after warming), plasma membrane integrity, acrosomal integrity, and spontaneous capacitation-like changes were determined after warming. Aseptic cryoprotectant-free vitrification showed a significantly stronger cryoprotective effect compared with conventional freezing. One hour after warming, motility, plasma membrane integrity, and acrosomal integrity were significantly higher than is observed for conventionally frozen spermatozoa (28% vs 18%, 56% vs 22%, and 55% vs 21%, respectively; P < .05), although lower than in fresh spermatozoa (35%, 96%, and 84%, respectively; P < .05). Capacitation-like changes did not differ significantly between vitrified and conventionally frozen samples (8% vs 9%, respectively; P > .1) (2% in fresh spermatozoa). The newly developed technology of aseptic vitrification of human spermatozoa in capillaries can effectively preserve these cells from cryo-injures. Spermatozoa, vitrified by this technology, are free from seminal plasma owing to swim-up preceding vitrification and are free from permeable cryoprotectants. They are ready for further use immediately after warming without any additional treatment. Therefore, the reported technology has a great potential for use in ICSI/IVF.
本研究的目的是开发并测试用于人类精子在毛细管中无渗透性冷冻保护剂玻璃化(用于卵胞浆内单精子注射[ICSI]或体外受精[IVF])的标准化无菌技术。为了测试玻璃化对精子基本参数的影响,将68份来自少弱畸精子症患者的经上游法处理的射精精液进行分装,并分为3组:1)未处理的对照组;2)10μL精子用含甘油的培养基通过传统慢速冷冻法冷冻保存;3)10μL精子在含有0.25M蔗糖的培养基中于50μL塑料毛细管中进行玻璃化。复温后测定精子活力(复温后1、24和48小时)、质膜完整性、顶体完整性和自发的类获能变化。与传统冷冻相比,无菌无冷冻保护剂玻璃化显示出显著更强的冷冻保护作用。复温1小时后,精子活力、质膜完整性和顶体完整性显著高于传统冷冻的精子(分别为28%对18%、56%对22%和55%对21%;P<.05),尽管低于新鲜精子(分别为35%、96%和84%;P<.05)。玻璃化和传统冷冻样本之间的类获能变化没有显著差异(分别为8%对9%;P>.1)(新鲜精子中为2%)。新开发的人类精子在毛细管中无菌玻璃化技术可有效保护这些细胞免受冷冻损伤。通过该技术玻璃化的精子,由于在玻璃化前进行了上游处理,不含精浆且不含渗透性冷冻保护剂。复温后无需任何额外处理即可立即进一步使用。因此,所报道的技术在ICSI/IVF中具有巨大的应用潜力。